BioSpace News Archive

Cullinan Oncology, Inc., (Nasdaq: CGEM) (“Cullinan Oncology”) today announced that posters of preclinical data highlighting the therapeutic potential of two assets, CLN-619 and CLN-617, will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, Florida, April 14-17, 2023.

Merus N.V. announced the selection of an abstract for a plenary session oral presentation that will highlight interim clinical data on the bispecific antibody petosemtamab in previously treated HNSCC along with the selection of a second abstract on petosemtamab in advanced gastric/esophageal adenocarcinoma for poster presentation at the AACR Annual Meeting 2023 taking place in Orlando, Florida April 14-19, 2023.

Merus N.V. announced the publication of an abstract highlighting the preclinical evaluation of the bispecific antibody MCLA-129 for poster presentation at the American Association for Cancer Research Annual Meeting 2023 taking place in Orlando, Florida April 14-19, 2023.

Affimed N.V. announced that two abstracts with clinical and preclinical data on AFM13, its anti-CD30 targeting innate cell engager, have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research, taking place April 14-19, 2022 in Orlando, Florida.

Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 – 19, 2023.

Delfi Diagnostics, Inc. will present multiple oral and poster presentations showcasing the performance of its next-generation liquid biopsy platform at the American Association for Cancer Research’s 2023 annual meeting next month.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that it is participating in the 2023 American Academy of Dermatology Annual Meeting, which will take place on March 17-21 in New Orleans.

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14 - 19, 2023 in Orlando, Florida.

Flare Therapeutics Inc. today announced that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 – 19, 2023.